The prevention and treatment of Plasmodium vivax malaria
Cindy S. Chu, Nicholas J. White
Abstract
The worldwide burden of Plasmodium vivax malaria has more than halved from an estimated 17.3 to 6.5 million cases between 2010 and 2019. This resulted from increased deployment of conventional malaria control measures (rapid diagnostic tests, effective antimalarial treatment, vector control) and significant global investment in malaria elimination. There is no generally available P. vivax vaccine, nor is there likely to be one in the near future.
Topics & Concepts
PrimaquineMalariaPlasmodium vivaxChloroquineHaemolysisMedicineAsymptomaticArtemisininImmunologyPlasmodium falciparumInternal medicineBiologyMalaria Research and ControlHemoglobinopathies and Related DisordersMosquito-borne diseases and control